<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-508
Date of Submission: 2025-01-21

This report was submitted by a Patient from Fisher, Smith and Francis Medical Center concerning patient ANON-PX-4291. The subject is a 80-year-old male with a significant medical history including seasonal allergies, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Subcutaneous route at a dosage of 197mg, initiated on 2024-11-03 for Neuropathic pain and discontinued on 2024-12-09; Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 489mg, initiated on 2024-11-03 for Gastroesophageal reflux disease and discontinued on 2024-12-09.

On approximately 2024-12-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Pruritus. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed own and advised the. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Hair discuss suffer lose opportunity very drug.</data>
report_id: ADR-2025-508
report_date: '2025-01-21'
patient_details:
  patient_id: ANON-PX-4291
  gender: Male
  relevant_history:
  - seasonal allergies
  - migraines
  age_at_reaction: 80
suspected_drugs:
- drug_name: Gabapentin
  dosage: 197mg
  route_of_administration: Subcutaneous
  start_date: '2024-11-03'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2024-12-09'
- drug_name: Omeprazole
  dosage: 489mg
  route_of_administration: Intravenous
  start_date: '2024-11-03'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2024-12-09'
adverse_reactions:
- symptom_name: Vomiting
  onset_date: '2024-12-02'
  severity: Moderate
  outcome: Recovered
  intervention_required: true
- symptom_name: Pruritus
  onset_date: '2024-12-02'
  severity: Mild
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed own and advised the.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Fisher, Smith and Francis Medical Center
reporter_type: Patient
notes: Hair discuss suffer lose opportunity very drug.
